Quincy Bioscience, LLC

Quincy Bioscience, LLC develops biotechnology products focused on cognitive enhancement, with its flagship product, Prevagen, designed to support memory and brain health. Founded in 2004 in Madison, US, Quincy Bioscience specializes in biotechnology with a focus on cognitive function enhancement. The company is led by CEO Michael Beaman, while Mark Underwood serves as the Founder. Quincy Bioscience has completed one major deal, with the most recent transaction occurring on June 4, 2014.

Quincy Bioscience specializes in the development and commercialization of innovative biotechnology products, focusing on Prevagen, an over-the-counter dietary supplement that supports cognitive function. Prevagen utilizes apoaequorin, a protein derived from jellyfish, and is targeted at individuals aiming to improve brain health, especially older adults. The product is available in the U. S.

through retail stores, pharmacies, and online platforms, and is compliant with industry standards and third-party certifications, ensuring quality for consumers. Quincy Bioscience generates revenue primarily through direct-to-consumer sales of its Prevagen product line, marketed in various formats like capsules and chewables. The company collaborates with retailers and wholesalers to ensure widespread distribution in health and wellness sectors, catering to individual consumers and retail chains. The pricing model for Prevagen aligns with industry standards for dietary supplements, with options to accommodate various customer needs and budgets.

Consistent marketing efforts and compliance with regulatory guidelines bolster the company's position in the health supplement market, contributing to revenue generation. Quincy Bioscience's future growth strategy includes the exploration of new products designed to enhance and expand its cognitive health offerings, although specific release dates have not been provided. The company aims to penetrate additional geographical markets beyond the U. S.

, although targeted regions and timelines have yet to be detailed. The funding received on June 4, 2014, will support these initiatives, enabling the company to invest in product development and market expansion efforts.